{"id":"https://openalex.org/W2091815896","doi":"https://doi.org/10.1002/pds.1443","title":"Coronary heart disease outcomes in patients receiving antidiabetic agents","display_name":"Coronary heart disease outcomes in patients receiving antidiabetic agents","alternate_titles":[],"publication_year":2007,"publication_date":"2007-06-06","ids":{"openalex":"https://openalex.org/W2091815896","doi":"https://doi.org/10.1002/pds.1443","mag":"2091815896","pmid":"https://pubmed.ncbi.nlm.nih.gov/17551989"},"language":"en","primary_location":{"id":"doi:10.1002/pds.1443","doi":"https://doi.org/10.1002/pds.1443","is_oa":false,"landing_page_url":"https://doi.org/10.1002/pds.1443","pdf_url":null,"source":{"id":"https://openalex.org/S140231191","display_name":"Pharmacoepidemiology and Drug Safety","issn_l":"1053-8569","issn":["1053-8569","1099-1557"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacoepidemiology and Drug Safety","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2091815896"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5010499068","display_name":"Andrew T. McAfee","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Andrew T. McAfee","raw_affiliation_strings":["i3 Drug Safety, Newton, Massachusetts 02451, USA. andrew.mcafee@i3drugsafety.com","Department of Emergency Medicine, Brigham and Women's Hospital, Boston, MA","i3 Drug Safety, Newton, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"i3 Drug Safety, Newton, Massachusetts 02451, USA. andrew.mcafee@i3drugsafety.com","institution_ids":[]},{"raw_affiliation_string":"Department of Emergency Medicine, Brigham and Women's Hospital, Boston, MA","institution_ids":["https://openalex.org/I1283280774"]},{"raw_affiliation_string":"i3 Drug Safety, Newton, Massachusetts","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006195570","display_name":"Carol E. Koro","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I126744593","display_name":"University of Maryland, Baltimore","ror":"https://ror.org/04rq5mt64","country_code":"US","type":"education","lineage":["https://openalex.org/I126744593"]},{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Carol Koro","raw_affiliation_strings":["Department of Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland, Baltimore, MD","GlaxoSmithKline, Collegeville, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland, Baltimore, MD","institution_ids":["https://openalex.org/I126744593"]},{"raw_affiliation_string":"GlaxoSmithKline, Collegeville, PA","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080151435","display_name":"Joan E. Landon","orcid":"https://orcid.org/0009-0009-7433-1826","observed_orcids":["https://orcid.org/0009-0009-7433-1826"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joan Landon","raw_affiliation_strings":["i3 Drug Safety, Newton, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"i3 Drug Safety, Newton, Massachusetts","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073130199","display_name":"Najat J. Ziyadeh","orcid":"https://orcid.org/0000-0002-7191-9140","observed_orcids":["https://orcid.org/0000-0002-7191-9140"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Najat Ziyadeh","raw_affiliation_strings":["i3 Drug Safety, Newton, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"i3 Drug Safety, Newton, Massachusetts","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5042449331","display_name":"Alexander Muir Walker","orcid":"https://orcid.org/0000-0001-9738-5127","observed_orcids":["https://orcid.org/0000-0001-9738-5127"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alexander M. Walker","raw_affiliation_strings":["i3 Drug Safety, Newton, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"i3 Drug Safety, Newton, Massachusetts","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5010499068"],"corresponding_institution_ids":["https://openalex.org/I1283280774"],"apc_list":{"value":4650,"currency":"USD","value_usd":4650},"apc_paid":null,"fwci":12.5111,"has_fulltext":false,"cited_by_count":109,"citation_normalized_percentile":{"value":0.99089109,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":99},"biblio":{"volume":"16","issue":"7","first_page":"711","last_page":"725"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9916999936103821,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9916999936103821,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10027","display_name":"Diabetes, Cardiovascular Risks, and Lipoproteins","score":0.004000000189989805,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/coronary-artery-disease","display_name":"coronary artery disease","score":0.8330000042915344},{"id":"https://openalex.org/keywords/myocardial-infarction","display_name":"myocardial infarction","score":0.9729999899864197},{"id":"https://openalex.org/keywords/coronary-revascularization","display_name":"coronary revascularization","score":0.9990000128746033},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9229999780654907},{"id":"https://openalex.org/keywords/oral-antidiabetic-drugs","display_name":"oral antidiabetic drugs","score":0.9160000085830688},{"id":"https://openalex.org/keywords/rosiglitazone","display_name":"rosiglitazone","score":0.9919999837875366},{"id":"https://openalex.org/keywords/metformin","display_name":"metformin","score":0.9990000128746033},{"id":"https://openalex.org/keywords/sulfonylureas","display_name":"sulfonylureas","score":0.9739999771118164},{"id":"https://openalex.org/keywords/insulin-therapy","display_name":"insulin therapy","score":0.843999981880188},{"id":"https://openalex.org/keywords/dual-therapy","display_name":"dual therapy","score":0.5569999814033508},{"id":"https://openalex.org/keywords/cardiovascular-risk","display_name":"cardiovascular risk","score":0.7950000166893005},{"id":"https://openalex.org/keywords/propensity-score-matching","display_name":"propensity score matching","score":0.6949999928474426}],"concepts":[{"id":"https://openalex.org/C2780152017","wikidata":"https://www.wikidata.org/wiki/Q424771","display_name":"Rosiglitazone","level":3,"score":0.9657944440841675},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9605121612548828},{"id":"https://openalex.org/C2780323712","wikidata":"https://www.wikidata.org/wiki/Q19484","display_name":"Metformin","level":3,"score":0.7391266822814941},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6870639324188232},{"id":"https://openalex.org/C2778384471","wikidata":"https://www.wikidata.org/wiki/Q417765","display_name":"Pioglitazone","level":4,"score":0.6080209612846375},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.5959475636482239},{"id":"https://openalex.org/C2778854520","wikidata":"https://www.wikidata.org/wiki/Q418776","display_name":"Sulfonylurea","level":3,"score":0.5754197835922241},{"id":"https://openalex.org/C500558357","wikidata":"https://www.wikidata.org/wiki/Q12152","display_name":"Myocardial infarction","level":2,"score":0.5677498579025269},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.5267341136932373},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.47217434644699097},{"id":"https://openalex.org/C2778213512","wikidata":"https://www.wikidata.org/wiki/Q844935","display_name":"Coronary artery disease","level":2,"score":0.45142027735710144},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.4142433702945709},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.2305976152420044}],"mesh":[{"descriptor_ui":"D000077154","descriptor_name":"Rosiglitazone","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006760","descriptor_name":"Hospitalization","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008687","descriptor_name":"Metformin","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D008687","descriptor_name":"Metformin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009203","descriptor_name":"Myocardial Infarction","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":true},{"descriptor_ui":"D009204","descriptor_name":"Myocardial Revascularization","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":true},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012307","descriptor_name":"Risk Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013453","descriptor_name":"Sulfonylurea Compounds","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D013453","descriptor_name":"Sulfonylurea Compounds","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D015331","descriptor_name":"Cohort Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015994","descriptor_name":"Incidence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045162","descriptor_name":"Thiazolidinediones","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D045162","descriptor_name":"Thiazolidinediones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1002/pds.1443","doi":"https://doi.org/10.1002/pds.1443","is_oa":false,"landing_page_url":"https://doi.org/10.1002/pds.1443","pdf_url":null,"source":{"id":"https://openalex.org/S140231191","display_name":"Pharmacoepidemiology and Drug Safety","issn_l":"1053-8569","issn":["1053-8569","1099-1557"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacoepidemiology and Drug Safety","raw_type":"journal-article"},{"id":"pmid:17551989","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17551989","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacoepidemiology and drug safety","raw_type":"Comparative Study"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307773","display_name":"GlaxoSmithKline","ror":"https://ror.org/01xsqw823"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":37,"referenced_works":["https://openalex.org/W1969067106","https://openalex.org/W1971267916","https://openalex.org/W1989377468","https://openalex.org/W1990450316","https://openalex.org/W1990589178","https://openalex.org/W2008380648","https://openalex.org/W2008674682","https://openalex.org/W2019955194","https://openalex.org/W2034649412","https://openalex.org/W2037668591","https://openalex.org/W2041779052","https://openalex.org/W2058403691","https://openalex.org/W2072205603","https://openalex.org/W2075378374","https://openalex.org/W2081276121","https://openalex.org/W2094394439","https://openalex.org/W2107166617","https://openalex.org/W2107176478","https://openalex.org/W2112546342","https://openalex.org/W2115211952","https://openalex.org/W2121065969","https://openalex.org/W2127125241","https://openalex.org/W2141855743","https://openalex.org/W2150291618","https://openalex.org/W2157494695","https://openalex.org/W2159969745","https://openalex.org/W2164367541","https://openalex.org/W2165882211","https://openalex.org/W2188846692","https://openalex.org/W2311863050","https://openalex.org/W2331274940","https://openalex.org/W2337454357","https://openalex.org/W2975364463","https://openalex.org/W4230518743","https://openalex.org/W4238251256","https://openalex.org/W4239785890","https://openalex.org/W4249825849"],"related_works":["https://openalex.org/W2010040970","https://openalex.org/W19591532","https://openalex.org/W2020353068","https://openalex.org/W2094662494","https://openalex.org/W1982820415","https://openalex.org/W2098550863","https://openalex.org/W2799901993","https://openalex.org/W2577890826","https://openalex.org/W1993112342","https://openalex.org/W2131490500"],"abstract_inverted_index":{"BACKGROUND:":[0],"There":[1,100,139],"is":[2],"conflicting":[3],"evidence":[4],"on":[5],"the":[6,22,71,105,108,144,177,180,185,211,214,226,239],"reduction":[7],"of":[8,24,86,90,95,107,146,179,184,188,228],"cardiovascular":[9,229],"risk":[10,23,106,145,178,227],"in":[11,32,143,150,161,176,223,232],"diabetic":[12,35],"patients":[13,36,233],"treated":[14,37],"with":[15,38,97,111,126,148,152,163,242],"oral":[16,158],"antidiabetic":[17,159],"agents.":[18],"OBJECTIVES:":[19],"To":[20],"compare":[21],"myocardial":[25],"infarction":[26],"(MI)":[27],"and":[28,66,73,92,124,190,213,246],"coronary":[29],"revascularization":[30],"(CR)":[31],"type":[33],"2":[34],"rosiglitazone,":[39],"metformin,":[40],"or":[41,60,183],"sulfonylurea.":[42],"METHODS:":[43],"Using":[44],"data":[45],"from":[46,76,210],"a":[47],"large":[48],"US":[49],"insurer,":[50],"we":[51],"created":[52],"propensity-matched":[53],"cohorts.":[54],"We":[55,62,82],"identified":[56,83],"hospitalizations":[57],"for":[58,70,199],"MI":[59,189],"CR.":[61],"calculated":[63],"incidence":[64],"rates":[65],"95%":[67,120,135,167,203],"confidence":[68],"intervals":[69],"outcomes":[72,187],"estimated":[74],"risks":[75,240],"Cox":[77],"proportional":[78],"hazards":[79],"models.":[80],"RESULTS:":[81],"26,931":[84],"initiators":[85,89,94],"monotherapy,":[87],"4,086":[88],"dual-therapy,":[91],"2,346":[93],"combination":[96,151,162],"insulin":[98,153,164],"therapy.":[99],"was":[101,140,173],"no":[102,141],"difference":[103,142,175],"between":[104,238],"composite":[109,181,200],"outcome":[110,147,182,201,230],"rosiglitazone":[112,127,149,193,235],"monotherapy":[113,117,128,132,212],"compared":[114,129,155],"to":[115,130,156,195],"metformin":[116,247],"(HR":[118,133,165,198],"1.07,":[119],"CI:":[121,136,168,204],"0.85,":[122],"1.34),":[123],"similarly":[125],"sulfonylurea":[131],"0.82,":[134],"0.67,":[137],"1.02).":[138],"therapy":[154],"other":[157],"agents":[160],"0.88,":[166],"0.59,":[169],"1.32).":[170],"Overall,":[171],"there":[172],"little":[174],"individual":[186],"CR":[191],"comparing":[192],"therapies":[194,197],"non-rosiglitazone":[196],"0.93,":[202],"0.80,":[205],"1.10).":[206],"CONCLUSIONS:":[207],"The":[208],"results":[209],"dual-therapy":[215],"comparisons,":[216],"though":[217],"not":[218],"individually":[219],"significant,":[220],"are":[221],"consistent":[222],"suggesting":[224],"that":[225],"events":[231],"using":[234],"may":[236],"lie":[237],"associated":[241],"sulfonylureas":[243],"(higher":[244],"incidence)":[245],"(lower":[248],"incidence).":[249]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2091815896","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":8},{"year":2012,"cited_by_count":7}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
